Table 4.

Treatment-Related Adverse Events with an Incidence ≥1%

Treatment-related adverse event	BBFC N=221 n (%)	Brinzolamide N=234 n (%)	Brimonidine N=235 n (%)
Ocular
Vision blurred	10 (4.5%)	16 (6.8%)	0 (0%)
Eye irritation	12 (5.4%)	4 (1.7%)	6 (2.6%)
Eye allergy	10 (4.5%)	0 (0%)	2 (0.9%)
Eye pain	6 (2.7%)	4 (1.7%)	3 (1.3%)
Eye pruritus	5 (2.3%)	3 (1.3%)	0 (0%)
Conjunctivitis	4 (1.8%)	0 (0%)	7 (3.0%)
Conjunctivitis allergic	4 (1.8%)	1 (0.4%)	5 (2.1%)
Conjunctival hyperemia	4 (1.8%)	1 (0.4%)	2 (0.9%)
Dry eye	4 (1.8%)	2 (0.9%)	1 (0.4%)
Lacrimation increased	3 (1.4%)	1 (0.4%)	1 (0.4%)
Ocular hyperemia	2 (0.9%)	1 (0.4%)	6 (2.6%)
Conjunctival follicles	1 (0.5%)	0 (0%)	3 (1.3%)
Non-ocular
Dysgeusia	9 (4.1%)	24 (10.3%)	1 (0.4%)
Dry mouth	6 (2.7%)	0 (0%)	5 (2.1%)
Fatigue	1 (0.5%)	0 (0%)	4 (1.7%)

Adverse events were analyzed using the safety population.